Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats

被引:6
作者
Trapani, AJ [1 ]
Beil, ME [1 ]
Bruseo, CW [1 ]
Fink, CA [1 ]
Hoyer, D [1 ]
Savage, P [1 ]
Jeng, AY [1 ]
机构
[1] Novartis Inst Biomed Res, Summit, NJ 07901 USA
关键词
CGS; 34225; atrial natriuretic peptide; big endothelin-1 pressor response; dual ECE/NEP inhibitor; endothelin converting enzyme; neutral endopeptidase 24.11;
D O I
10.1042/CS103S102S
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
CGS 34226 is a thiol-containing, potent dual inhibitor of endothelin converting enzyme-1 (ECE-1) and neutral endopeptidase 24.11 (NEP) with IC50 values of 11 and 5 nM respectively. The purpose of the present study was to characterize the inhibitory effects of CGS 34225, an orally active prodrug of CGS 34226, on ECE-1 and NEP in vivo. The effects on ECE-1 and NEP were assessed by determining the inhibition of big endothelin-1 (big ET-1)-induced increases in mean arterial pressure (MAP) and increases in plasma atrial natriuretic peptide (ANP) concentrations respectively, in conscious rats. Thirty and 120 min after the administration of vehicle, big ET-1 (0.3 nmol/kg, intravenously; i.v.) produced pressor responses of approximately 800 mmHg . min (area under the curve for change in MAP x time). Treatment with CGS 34225 at 1 mgEq/kg, per os (p.o.), decreased the pressor effect of big ET-1 by 39 and 53% at 30 and 120 min respectively (P < 0.05, both times). Increasing the dose of CGS 34255 to 30 mgEq/kg, p.o., resulted in greater inhibition, 84 and 92% (P < 0.05) at 30 and 120 min respectively. Furthermore, at this higher dose, the inhibitory effect on ECE-1 was long-lasting, averaging 86, 75 and 30% (P < 0.05, all times) at 4, 8 and 24 h respectively. In rats treated with vehicle, the infusion of ANP at 450 ng/kg per min i.v. resulted in plasma ANP concentrations of 3.9-4.8 ng/ml that remained relatively constant for 4 h. Treatment with CGS 34225 at 10 mgEq/kg, p.o., increased the ANP level to 7.7 +/- 1.0 and 10.6 +/- 1.8 ng/ml at 1 and 4 h after dosing (P < 0.05, both times). These data demonstrate that CGS 34225 is a potent, orally active and long-acting inhibitor of ECE-1 and NEP in vivo. It is anticipated that compounds with this dual function may be useful in the treatment of cardiovascular diseases where the ET system plays a pathogenic role and the potentiation of ANP elicits therapeutic benefits.
引用
收藏
页码:102S / 106S
页数:5
相关论文
共 27 条
  • [1] ETA receptor blockade attenuates the hypertension but not renal dysfunction in DOCA-salt rats
    Allcock, GH
    Venema, RC
    Pollock, DM
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 1998, 275 (01) : R245 - R252
  • [2] Chatelain RE, 1998, J PHARMACOL EXP THER, V284, P974
  • [3] CHENG XM, 1994, CURR MED CHEM, V1, P271
  • [4] UK-69,578, A NOVEL INHIBITOR OF EC-342411 WHICH INCREASES ENDOGENOUS ANF LEVELS AND IS NATRIURETIC AND DIURETIC
    DANILEWICZ, JC
    BARCLAY, PL
    BARNISH, IT
    BROWN, D
    CAMPBELL, SF
    JAMES, K
    SAMUELS, GMR
    TERRETT, NK
    WYTHES, MJ
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 164 (01) : 58 - 65
  • [5] Design and synthesis of potent thiol-based inhibitors of endothelin converting enzyme-1
    Fink, CA
    Moskal, M
    Firooznia, F
    Hoyer, D
    Symonsbergen, D
    Wei, DC
    Qiao, Y
    Savage, P
    Beil, ME
    Trapani, AJ
    Jeng, AY
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (17) : 2037 - 2039
  • [6] Molecular pharmacology and pathophysiological significance of endothelin
    Goto, K
    Hama, H
    Kasuya, Y
    [J]. JAPANESE JOURNAL OF PHARMACOLOGY, 1996, 72 (04) : 261 - 290
  • [7] Jeng AY, 2002, CLIN SCI, V103, p98S
  • [8] Jeng AY, 1997, CURR PHARM DESIGN, V3, P597
  • [9] Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats
    Kassab, S
    Miller, MT
    Novak, J
    Reckelhoff, J
    Glower, B
    Granger, JP
    [J]. HYPERTENSION, 1998, 31 (01) : 397 - 402
  • [10] Endothelin system: The double-edged sword in health and disease
    Kedzierski, RM
    Yanagisawa, M
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 : 851 - 876